| NCT ID | NCT07209202 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Touro University, California |
| Condition | Healthy Participants |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-03-02 |
| Primary Completion | 2030-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-03-02 with a primary completion date of 2030-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will test the hypothesis that within a defined range of fructose intake, the ability to convert fructose to glucose (via gluconeogenesis) in the small intestine plays a protective role for the liver, shielding it from the deleterious effects of fructose. We will investigate whether this protective effect of the intestine is impaired in individuals with obesity.
Eligibility Criteria
Inclusion Criteria: * BMI 30 to 38 kg/m2 (obese group) or BMI 19 to 25 kg/m2 (lean group) Exclusion Criteria: * Pregnancy or lactation within the past six months; * Type 1 or 2 diabetes mellitus (including fasting glucose ≥126 mg/dL, HgbA1c ≥6.5%); * History of liver disease or AST and ALT 2x above the upper limit of normal; * Fasting triglyceride \> 300 mg/dl; total cholesterol levels above the 95th percentile for age and sex; * Hemoglobin (Hgb) \<12.5g/d or hematocrit\<3x Hgb value; * Report of HIV or hepatitis B or C infection; * History of cancer, other than basal cell or squamous cell carcinoma or kidney disease stage 3 or higher or patients currently on dialysis; * Use of any anti-diabetic medications or hypolipidemic agents in the past six months; * History of surgical procedure for obesity; * Change in body weight \>5% in the past six months (by self-report); * History of other conditions known to affect insulin sensitivity and lipid metabolism (e.g., polycystic ovary syndrome), history of galactosemia, hereditary fructose intolerance, or who test positive for fructose malabsorption at screening; * Known intolerance to acetaminophen.
Contact & Investigator
Jean-Marc Schwarz, PhD
PRINCIPAL INVESTIGATOR
Touro University, California
Frequently Asked Questions
Who can join the NCT07209202 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 55 Years, studying Healthy Participants. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07209202 currently recruiting?
Yes, NCT07209202 is actively recruiting participants. Contact the research team at schiu2@touro.edu for enrollment information.
Where is the NCT07209202 trial being conducted?
This trial is being conducted at Vallejo, United States.
Who is sponsoring the NCT07209202 clinical trial?
NCT07209202 is sponsored by Touro University, California. The principal investigator is Jean-Marc Schwarz, PhD at Touro University, California. The trial plans to enroll 40 participants.